Cochrane for Clinicians

Putting Evidence into Practice

Use of Amphetamines for Attention-Deficit/Hyperactivity Disorder in Adults


Am Fam Physician. 2019 Sep 1;100(5):278-279.

Author disclosure: No relevant financial affiliations.

Clinical Question

Are amphetamines safe and effective in adults with attention-deficit/hyperactivity disorder (ADHD)?

Evidence-Based Answer

Amphetamines provide a clinician-rated 30% or greater reduction in ADHD symptoms when compared with placebo (number needed to treat = 5).1 (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)

Practice Pointers

ADHD is a neurodevelopmental disorder with a mean onset at six years of age. Approximately one-third of affected children will carry the disorder into adulthood; the current prevalence of ADHD in U.S. adults is 4.4%.2 ADHD symptoms present differently in adults than in children. Hyperactivity and impulsivity in adults often appear as restlessness, talkativeness, and emotional dysregulation (i.e., irritability, emotional lability, and emotional reactivity). Inattention manifests similarly in childhood and adulthood. The use of amphetamines for the treatment of adult ADHD has increased, and this Cochrane review analyzed their safety and effectiveness.1

The review included 19 randomized controlled trials (2,521 adults with ADHD) comparing dextroamphetamine, lisdexamfetamine (Vyvanse), or mixed amphetamine salts with placebo. Studies lasted on average 5.3 weeks (range: one to 20 weeks), with only three studies (N = 542) lasting more than eight weeks. The participants had a mean age of 35.3 years, and most (57.2%) were men; 78.8% had combined-type ADHD. The primary outcome was the severity of ADHD symptoms, assessed by clinicians or participants using the standardized ADHD Rating Scale-IV (ADHD-RS-IV). Secondary outcomes included clinical impressions of ADHD symptom severity and improvement at study end based on the Clinical Global Impression Severity and Impression Scales (CGI-S and CGI-I, respectively); percentage of participants with a 30% reduction in ADHD symptoms (measured by the ADHD-RS-IV) and/or a CGI-I score of 1 or 2; global functioning based on the CGI-S; symptoms of depression and anxiety per standardized instruments chosen by the individual study; treatment adherence; and adverse effects. The review had several limitations: no study had a low risk of bias, 16 of the 19 studies were funded by pharmaceutical companies, there was attrition bias because adverse effects of amphetamines may have been present, and the reviewers were to rule out carryover effects in studies with a crossover design.1

Low- to very low-quality evidence demonstrated that amphetamines, as a group, were effective in reducing the severity of ADHD symptoms as rated by clinicians (standardized mean difference [SMD] = −0.90; 95% CI, −1.04 to −0.75; P < .00001; 13 studies; 2,028 participants) and participants (SMD = −0.51; 95% CI, −0.75 to −0.28; P < .000021; six studies; 120 participants) using the ADHD-RS-IV. Not all amphetamines performed equally. Lisdexamfetamine (SMD = −1.06; 95% CI, −1.26 to −0.85; seven studies; 896 participants) and mixed amphetamine salts (SMD = −0.80; 95% CI, −0.93 to −0.66; five studies; 1,083 participants) reduced clinician-rated severity of symptoms, whereas dextroamphetamine did not. The review also found that dextroamphetamine and lisdexamfetamine, but not mixed amphetamine salts, significantly reduced participant-rated severity of ADHD symptoms compared with placebo (dextroamphetamine: SMD = −0.77; 95% CI, −1.14 to −0.40; two studies; 35 participants; lisdexamfetamine: SMD = −0.33; 95% CI, −0.65 to −0.01; three studies; 67 participants; and mixed amphetamine salts: SMD = −0.45; 95% CI, −1.02 to 0.12; one study; 18 participants).1

Amphetamines were not effective at improving global functioning based on the CGI-S Scale or at reducing symptoms of depression and anxiety (based on various standardized instruments used across different studies). Low vs. high dose (low dose defined as less than 16 mg per day for dextroamphetamine, 53.4 mg per day for lisdexamfetamine, and 50 mg per day for mixed amphetamine salts), type of formulation (immediate or sustained release), and the presence of a comorbidity (drug-use disorder or depression) did not affect the severity of ADHD symptoms as assessed by clinicians or participants. A meta-analysis of 17 studies (N = 2,409) found a greater risk of dropout from any adverse effect with amphetamines than with placebo (relative risk = 2.69; 95% CI, 1.63 to 4.42), although withdrawal by participants treated with amphetamines was considered low at 7.6% (placebo drop-out rate was 2.4%).1 Adverse effects leading to withdrawal included anxiety, depressed mood, nausea/vomiting, headache, fatigue, insomnia, increased blood pressure, flushing, and affective dullness.39 Most reported adverse effects were considered mild to moderate.

The National Institute for Health and Care Excellence (NICE) guidelines for managing adult ADHD recommend implementing environmental modifications initially, and offering medications such as lisdexamfetamine or methylphenidate (Ritalin) only in a shared decision-making model with routine follow-up.10 When adults are taking amphetamines, it is recommended that weight, heart rate, blood pressure, and sleep patterns be monitored with every medication change and every six months because of potential cardiovascular events. This Cochrane review supports the NICE guidelines.1,10

The practice recommendations in this activity are available at

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army Medical Department or the U.S. Army Service at large.

Author disclosure: No relevant financial affiliations.


show all references

1. Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018;(8):CD007813....

2. National Institute of Mental Health. Attention-deficit/hyperactivity disorder (ADHD). November 2017. Accessed September 17, 2018.

3. Adler LA, Goodman D, Weisler R, et al. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct. 2009;5:34.

4. Weisler RH, Greenbaum M, Arnold V, et al. Efficacy and safety of SHP465 mixed amphetamine salts in the treatment of attention-deficit/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled, forced-dose clinical study. CNS Drugs. 2017;31(8):685–697.

5. Martin PT, Corcoran M, Zhang P, et al. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder. Clin Drug Investig. 2014;34(2):147–157.

6. Kollins SH, English JS, Itchon-Ramos N, et al. A pilot study of lisdexamfetamine dimesylate (LDX/SPD489) to facilitate smoking cessation in nicotine-dependent adults with ADHD. J Atten Disord. 2014;18(2):158–168.

7. Kay GG, Michaels MA, Pakull B. Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine. J Atten Disord. 2009;12(4):316–329.

8. Frick G, Yan B, Adler LA. Triple-bead mixed amphetamine salts (SHP465) in adults with ADHD: results of a phase 3, double-blind, randomized, forced-dose trial [published online April 1, 2017]. J Atten Disord. Accessed September 17, 2018.

9. Biederman J, Fried R, Hammerness P, et al. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatr Res. 2012;46(4):484–491.

10. National Institute for Health and Care Excellence Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. March 2018. Accessed September 17, 2018.

These are summaries of reviews from the Cochrane Library.

This series is coordinated by Corey D. Fogleman, MD, Assistant Medical Editor.

A collection of Cochrane for Clinicians published in AFP is available at



Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in Pubmed


Jan 15, 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article